TESARO Inc (TSRO) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-2.22 earnings per share for the quarter, missing the analyst consensus estimate by $-0.54. Analysts had a consensus of $-1.68. The company posted revenue of $.31 million in the period, compared to analysts expectations of $3.54 million. During the same quarter in the previous year, the company posted $-1.30 EPS.
Many Wall Street Analysts have commented on TESARO Inc. FBR Capital Initiated TESARO Inc on Apr 13, 2016 to “Outperform”, Price Target of the shares are set at $65.Sun Trust Rbsn Humphrey Initiated TESARO Inc on Mar 2, 2016 to “Buy”, Price Target of the shares are set at $60.
TESARO Inc closed down -0.83 points or -2.03% at $40.06 with 6,29,319 shares getting traded on Wednesday. Post opening the session at $40.62, the shares hit an intraday low of $39.57 and an intraday high of $40.91 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price. According to the SEC, on Mar 18, 2016, Arnold L Oronsky (director) purchased 142,085 shares at $35.19 per share price. On Mar 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $43.54 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.